Arena Pharmaceuticals

Aristea Halts Clinical Trial, Dissolves Company

Safety findings in Phase 2 clinical trials have forced Aristea Therapeutics to stop developing its lead candidate RIST4721 for treating serious immune-mediated inflammatory diseases. As a consequence, Aristea’s management has decided to dissolve the company.

News

Vivus Obesity Pill Prescriptions Jump 68%

News

FDA OKs First Obesity Drug in 13 years

Top-Feature

Together for Sustanability (TFS)

Industry Kick-Off with Signal Effect: More Than 310 Exhibitors expected at maintenance and PUMPS & VALVES 2026

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Sasol

Leading Transformation

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Arena Pharmaceuticals

Aristea Halts Clinical Trial, Dissolves Company

Vivus Obesity Pill Prescriptions Jump 68%

FDA OKs First Obesity Drug in 13 years

Top-Feature

Driving Sustainability Through Collaboration

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Europe’s Biotech Inflection Point

API Manufacturing

Leading the way. Driving results.

Anchored in Sustainability